Modelling COVID-19 vaccination in the UK: impact of the autumn 2022 and spring 2023 booster campaigns
Budget impact of oral nirmatrelvir/ritonavir in adults at high risk for progression to severe COVID-19 in the United States
An economic evaluation estimating the clinical and economic burden of increased vancomycin-resistant enterococcus faecium infection incidence in Japan
Virologic response to dolutegravir plus lamivudine in people with suppressed human immunodeficiency virus type 1 and historical M184V/I: a systematic literature review and meta-analysis
Capturing value attributes in the economic evaluation of ceftazidime with avibactam for treating severe aerobic gram-negative bacterial infections in the United Kingdom
Quantifying the economic and clinical value of reducing antimicrobial resistance in gram-negative pathogens causing hospital-acquired infections in Australia
Clinical and economic value of reducing antimicrobial resistance in the management of hospital-acquired infections with limited treatment options in Greece
Cabotegravir and rilpivirine long-acting antiretroviral therapy administered every 2 months is cost-effective for the treatment of HIV-1 in Spain
Estimating the treatment and prophylactic economic value of new antimicrobials in managing antibiotic resistance and serious infections for common pathogens in the USA: a population modelling study
